financetom
Business
financetom
/
Business
/
Semler Scientific Stock Is Surging Thursday: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Semler Scientific Stock Is Surging Thursday: What's Going On?
Nov 21, 2024 6:42 PM

Semler Scientific, Inc. ( SMLR ) shares are trading higher Thursday potentially following the company's recent announcement about its Bitcoin (CRYPTO: BTC/USD) activity, capital markets updates and performance indicators. Here’s what you need to know.

What To Know: Multiple crypto-linked stocks are moving higher on Thursday after Bitcoin hit new all-time highs above $98,000. Some names are outperforming and it appears to be a result of recent Bitcoin accumulation strategies.

MicroStrategy and MARA Holdings have outperformed peers in recent trading sessions. Both companies recently completed offerings and used the proceeds to buy additional Bitcoin as they focus on stockpiling.

Semler Scientific ( SMLR ) has also adopted a Bitcoin treasury strategy. The company announced it raised $21.5 million through the sale of 505,544 shares of its common stock under an at-the-market offering earlier this week. The proceeds partially funded the company’s recent Bitcoin purchases.

Semler said it purchased 215 Bitcoin for $17.7 million in cash at an average price of $82,502 between Nov. 6 and Nov. 15. The company now holds a total of 1,273 Bitcoin, acquired for a total cost of $88.7 million.

The rise in Semler's stock price suggests investors are optimistic about the company's strategic use of equity to expand its Bitcoin holdings.

SMLR Price Action: Semler Scientific ( SMLR ) shares were up 18.9% at $70.50 at the time of publication, according to Benzinga Pro.

Read Next:

Paying $6.24 Million For A Duct-Taped Banana? Justin Sun Did Just That — And Now He’ll Eat It ‘As Part Of This Unique Artistic Experience’

Image Via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verizon, Santander Bank Partner to Offer Openbank High-Yield Savings Account
Verizon, Santander Bank Partner to Offer Openbank High-Yield Savings Account
Mar 18, 2025
03:52 PM EDT, 03/18/2025 (MT Newswires) -- Verizon Communications ( VZ ) is partnering with Santander Bank, the US subsidiary of Banco Santander (SAN), to offer a high-yield savings account through Openbank, the companies said Tuesday. Starting in April, Verizon customers can sign up for Verizon + Openbank Savings, which offers an annual percentage yield of 4.40%, about 10 times...
USDOJ in talks with Southwest Airlines to resolve delayed flights lawsuit
USDOJ in talks with Southwest Airlines to resolve delayed flights lawsuit
Mar 18, 2025
WASHINGTON (Reuters) - The Justice Department on Tuesday said it is in talks with Southwest Airlines ( LUV ) about potentially resolving a suit filed by the Biden administration accusing the carrier of illegally operating chronically delayed flights. The U.S. Transportation Department in January said Southwest ( LUV ) had operated unrealistic schedules, and said it was seeking maximum civil...
Cna Financial Insider Sold Shares Worth $637,338, According to a Recent SEC Filing
Cna Financial Insider Sold Shares Worth $637,338, According to a Recent SEC Filing
Mar 18, 2025
04:04 PM EDT, 03/18/2025 (MT Newswires) -- Daniel Paul Franzetti, Executive Vice President and Chief Administrative Officer, on March 15, 2025, sold 12,991 shares in Cna Financial ( CNA ) for $637,338. Following the Form 4 filing with the SEC, Franzetti has control over a total of 75,612 common shares of the company, with 75,612 shares held directly. SEC Filing:...
Sarepta says teen died after its gene therapy treatment
Sarepta says teen died after its gene therapy treatment
Mar 18, 2025
(Reuters) - Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient underwent treatment in December with Sarepta's therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys is the only FDA-approved gene therapy for Duchenne muscular dystrophy (DMD)...
Copyright 2023-2026 - www.financetom.com All Rights Reserved